Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1223

1.

The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.

Franco I, Landau-Dyer L, Isom-Batz G, Collett T, Reda EF.

J Urol. 2007 Oct;178(4 Pt 2):1775-9; discussion 1779-80. Epub 2007 Aug 17.

PMID:
17707430
2.

Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder.

Mokhless I, Gaafar S, Fouda K, Shafik M, Assem A.

J Urol. 2006 Oct;176(4 Pt 2):1767-70; discussion 1770.

PMID:
16945643
3.

Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.

Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB.

Urology. 2005 Jan;65(1):37-41.

PMID:
15667859
4.

Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B.

J Urol. 2006 Jul;176(1):177-85.

PMID:
16753396
5.
6.

Botulinum toxin as a new therapy option for voiding disorders: current state of the art.

Leippold T, Reitz A, Schurch B.

Eur Urol. 2003 Aug;44(2):165-74. Review.

PMID:
12875934
8.

Changing concepts concerning the management of vesicoureteral reflux.

Herndon CD, DeCambre M, McKenna PH.

J Urol. 2001 Oct;166(4):1439-43.

PMID:
11547107
9.

Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients.

Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1670-6.

10.

Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction.

Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB.

J Urol. 2001 Apr;165(4):1107-10.

PMID:
11257648
11.

Botulinum toxin type A in combination with standard urotherapy for children with dysfunctional voiding.

Petronijevic V, Lazovic M, Vlajkovic M, Slavkovic A, Golubovic E, Miljkovic P.

J Urol. 2007 Dec;178(6):2599-602; discussion 2602-3. Epub 2007 Oct 22.

PMID:
17945299
12.

Improved uroflow parameters and post-void residual following biofeedback therapy in pediatric patients with dysfunctional voiding does not correspond to outcome.

Nelson JD, Cooper CS, Boyt MA, Hawtrey CE, Austin JC.

J Urol. 2004 Oct;172(4 Pt 2):1653-6; discussion 1656.

PMID:
15371783
14.

Long-term efficacy and durability of botulinum-A toxin for refractory dysfunctional voiding in children.

Vricella GJ, Campigotto M, Coplen DE, Traxel EJ, Austin PF.

J Urol. 2014 May;191(5 Suppl):1586-91. doi: 10.1016/j.juro.2013.10.034. Epub 2014 Mar 26.

PMID:
24679879
15.

The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor.

Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, Van Laecke E.

J Urol. 2006 Jul;176(1):328-30; discussion 330-1.

PMID:
16753434
16.
17.

Dysfunctional voiding in women.

Carlson KV, Rome S, Nitti VW.

J Urol. 2001 Jan;165(1):143-7; discussion 147-8.

PMID:
11125384
18.

Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity.

Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K.

Urology. 2005 Oct;66(4):865-70; discussion 870.

PMID:
16230156
19.

Pelvic floor muscle retraining for pediatric voiding dysfunction using interactive computer games.

McKenna PH, Herndon CD, Connery S, Ferrer FA.

J Urol. 1999 Sep;162(3 Pt 2):1056-62; discussion 1062-3.

PMID:
10458431
20.

Is it reasonable to treat refractory voiding dysfunction in children with botulinum-A toxin?

Radojicic ZI, Perovic SV, Milic NM.

J Urol. 2006 Jul;176(1):332-6; discussion 336.

PMID:
16753436

Supplemental Content

Support Center